Diastolic function is a strong predictor of mortality in patients with chronic kidney disease

[11] Sarnak MJ(2009)Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 107-2538

[12] Levey AS(2007)Universal definition of myocardial infarction Eur Heart J 28 2525-1140

[13] Schoolwerth AC(2005)Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology Eur Heart J 26 1115-2032

[14] Coresh J(2009)A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2019-2192

[15] Culleton B(2011)The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial Lancet 377 2181-902

[16] Hamm LL(2011)Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry Am J Kidney Dis 57 894-755

[17] McCullough PA(2011)Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT) Am Heart J 16 748-678

[18] Kasiske BL(2013)Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the chronic renal insufficiency Cohort (CRIC) Study Am J Kidney Dis 62 670-44

[19] Kelepouris E(1990)Diffuse intermyocardiocytic fibrosis in uraemic patients Nephrol Dial Transplant 5 39-113

[20] Klag MJ(2001)The heart in renal failure: morphological changes of the myocardium - new insights J Clin Basic Cardiol 4 109-2031

[11] Sarnak MJ(2009)Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 107-2538

[12] Levey AS(2007)Universal definition of myocardial infarction Eur Heart J 28 2525-1140

[13] Schoolwerth AC(2005)Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology Eur Heart J 26 1115-2032

[14] Coresh J(2009)A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2019-2192

[15] Culleton B(2011)The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial Lancet 377 2181-902

[16] Hamm LL(2011)Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry Am J Kidney Dis 57 894-755

[17] McCullough PA(2011)Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT) Am Heart J 16 748-678

[18] Kasiske BL(2013)Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the chronic renal insufficiency Cohort (CRIC) Study Am J Kidney Dis 62 670-44

[19] Kelepouris E(1990)Diffuse intermyocardiocytic fibrosis in uraemic patients Nephrol Dial Transplant 5 39-113

[20] Klag MJ(2001)The heart in renal failure: morphological changes of the myocardium - new insights J Clin Basic Cardiol 4 109-2031